Fig. 2From: Meeting patient expectations in migraine treatment: what are the key endpoints?SPF versus adverse event rates for different triptans. Derived from a meta-analysis of 53 trials involving 24,089 patients [9]. Data for frovatriptan unavailable. After Dodick et al. (2007)CNS Drugs 21 (1):73–82 with permission. A Almotriptan, E eletriptan, N naratriptan, R rizatriptan, Z zolmitriptanBack to article page